Lisa Henderson

Next week at DIA, two of TransCelerate?s Risk Based Monitoring workstream members will take their newly released methodology to the people.

Risk-based monitoring was in Trans-Celerate BioPharma's sights since the pharmaceutical company collaborative was announced in September 2012.

This year, CBI will be co-locating their Risk-Based Monitoring in Clinical Studies conference and Clinical Patient Engagement Summit this October 24-25, 2013 in Philadelphia.

In the podcast, Kent Thoelke, Executive Vice Presdient, Scientific & Medical Affairs for PRA, discuss parallel drug development strategies in China, the nuances of the regulatory market there, as well as best practices.

The rocky economy continues to wreak havoc on employment and drug development.

Industry news focusing on the people and organizations who work in the clinical trials profession.

Last October, Outcome Sciences announced its collaboration with the National Football League to update its Injury Surveillance System (ISS), since then, the pilot has been completed during the course of the 2011 NFL season and rolled out to all the teams for 2012.

In August last year, the FDA came out with its Guidance for Industry Oversight of Clinical Investigations-a Risk-Based Approach to Monitoring. Sponsors and CROs alike are still examining the document and discussing how best to move forward.